x
x
Disclaimer

The U.S. section of Abbottep.com is a product-specific website that is NOT intended for non U.S. residents. This web content is exclusively reserved for health care professionals in the United States.

Do you wish to continue to visit the Abbottep.com U.S. section?

Get your rhythm back.

Serious heart rhythm disorders called arrhythmias, affect the lives of millions of people daily. Unfortunately, most treatments for these conditions are generic and one-size-fits-all, with mixed results.


But there’s hope.


We believe there is a better way to treat serious heart rhythm disorders such as atrial fibrillation and ventricular tachycardia. Using Abbott Electrophysiology’s technology, doctors can identify the sources of arrhythmias that are unique to each person. Now treatment can be tailored to your individual needs.


Find Your Source.
Get Tailored Therapy.
Get Your Rhythm Back.

Find a doctor near you who is using the Topera Rotor Mapping System

The most common heart rhythm disorder, atrial fibrillation (AF, or afib) is a serious global public health problem which affects millions of people around the world. If left untreated, AF doubles the risk of heart-related deaths and also increases stroke risk by up to 500%. Unfortunately, although it is such a serious health problem, AF has historically been difficult to treat with an acceptable degree of success.

In response to this unaddressed need, Abbott, Inc. has developed a unique 3D analysis and mapping solution (the Abbott 3D Mapping System), which consists of the RhythmView Workstation and FIRMap diagnostic catheter. The Abbott 3D Mapping System has been designed to enable physicians to view the electrical activity of the heart, thereby supporting the diagnosis and patient-specific treatment planning for a variety of heart arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia, and ventricular tachycardia.

The Abbott 3D Mapping System received FDA clearance in 2013 and is now in routine use at several leading medical centers throughout the United States.

Press Releases

St. Jude Medical and Abbott to Sell Portion of Vascular Closure and Electrophysiology Businesses to Terumo Corporation
ABBOTT PARK, Ill. and ST. PAUL, Minn., Oct. 18, 2016 — Abbott and St. Jude Medical, Inc.  announced today an agreement in principle to sell
Abbott Announces Positive Clinical Results from Studies of FIRM-Guided Rotor Ablation for Atrial Fibrillation
Abbott Announces Positive Clinical Results from Studies of FIRM-Guided Rotor Ablation for Atrial Fibrillation ABBOTT PARK, Ill., June. 22, 2016 — Abbott announced today positive
Abbott Acquires Kalila Medical to Expand Cardiac Electrophysiology Offerings
ABBOTT PARK, Ill., Feb. 2, 2016 — Abbott announced today that it has acquired Kalila Medical, Inc., a private medical device company developing next-generation access technologies used in cardiac electrophysiology
Abbott Expands Its Medical Device Business with Acquisition in Catheter-Based Electrophysiology Market
Abbott Enters Large and Growing Catheter-Based Electrophysiology Market with Next-Generation Technologies to Improve Treatment of People with Atrial Fibrillation ABBOTT PARK, Ill., Oct. 29, 2014
FDA-cleared RhythmView Rotor mapping workstation will be discussed in 21 scientific presentations
Topera today announced that its FDA-cleared RhythmView Rotor mapping workstation will be discussed in 21 scientific presentations at the 34th Annual Scientific Sessions of the
Topera today announced that it has received 510(k)
Topera today announced that it has received 510(k) clearance by the U.S Food and Drug Administration (FDA) for the latest generation of its Roitor Mapping
Abbott Electrophysiology today shared the results
Topera today shared the results of an independent evaluation of its diagnostic system’s ability to improve AF outcomes by identifying of the sources that sustain
Abbott Electrophysiology today announced the 510(k) clearance
Abbott today announced the 510(k) clearance by the U.S. Food and Drug Administration (FDA) for the FIRMap Catheter and its U.S. commercial availability. “Securing the
Abbott Electrophysiology today announced it has completed a $25 million Series C financing round
Abbott today announced it has completed a $25 million Series C financing round. The round was led by new investor New Enterprise Associates (NEA) with
Featured in 8 presentations at the 2012 American Heart Association Scientific Sessions
Topera today announced that its RhythmView™ Rotor Electrophysiological Mapping System will be featured in 8 presentations at the 2012 American Heart Association Scientific Sessions, November
1 |